Evidence map›Paper›PMID 42606826›Full record

ArticleJournal of biochemical and molecular toxicology2026

SLC3A1 Mitigates Ferroptosis and Promotes Enzalutamide Resistance in Prostate Cancer.

Peng Liu, Haocheng Zhang, Yuhang Qian, Jiong Zhang, Xiaojun Deng, Bin Sun

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of biochemical and molecular toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Peng LiuDepartment of Urology, 411 Hospital of Shanghai University, Shanghai, China.
Haocheng ZhangDepartment of Urology, 411 Hospital of Shanghai University, Shanghai, China.
Yuhang QianDepartment of Urology, 411 Hospital of Shanghai University, Shanghai, China.ORCID https://orcid.org/0009-0001-7316-5995
Jiong ZhangDepartment of Urology, 411 Hospital of Shanghai University, Shanghai, China.
Xiaojun DengDepartment of Urology, 411 Hospital of Shanghai University, Shanghai, China.
Bin SunDepartment of Urology, 411 Hospital of Shanghai University, Shanghai, China.

Funding

Medical Research Project of Hongkou District Health Commission 2403-17
6 · The paper itself

Abstract

Prostate cancer (PCa) remains a leading cause of cancer-related mortality in aging male, with resistance to enzalutamide (Enza) representing a major therapeutic challenge. This study identifies SLC3A1 as a key driver of Enza resistance. Through integrative bioinformatics analysis of GEO datasets, we found SLC3A1 significantly upregulated in Enza-resistant PCa models. WGCNA and single-cell RNA sequencing confirmed its association with adverse prognosis and activation of key survival pathways. Functional experiments demonstrated that SLC3A1 knockdown reduced AKT phosphorylation, and inhibited colony formation in LNCaP cells. Conversely, SLC3A1 overexpression activated PI3K-AKT signaling, suppressed ferroptosis and conferred Enza resistance in vitro and in vivo. These results reveal SLC3A1 is a promising therapeutic target for advanced prostate cancer.

Indexed as

Amino Acid Transport Systems, BasicDrug Resistance, NeoplasmFerroptosisNeoplasm ProteinsPhenylthiohydantoinProstatic NeoplasmsAnimalsBenzamidesCell Line, TumorHumansMaleMiceNitrilesSignal TransductionAmino Acid Transport Systems, BasicBenzamidesenzalutamideNeoplasm ProteinsNitrilesPhenylthiohydantoinenzalutamideGEOprostate cancerSLC3A1WGCNA

Identifiers

PMID42606826
PMCPMC13480344

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.